Back to results
US 12,758,647 B2Granted
Anti-CSPG4 binding agents, encoding nucleic acids thereof, conjugates thereof and methods of use thereof to treat a CSPG4+ cancer
AssigneeArdeagen Corporation
InventorsMaria Leia Smith, May Kung Sutherland
Life of this patent
Estimating the term…
Abstract
The present disclosure provides anti-CSPG4 antibodies, antigen binding portions thereof and CSPG4 conjugates thereof for use in the treatment of cancer.
Claims41
A binding agent comprising:
- (a) a heavy chain variable (VH) region having the amino acid sequence set forth in SEQ ID NO:25, and a light chain variable (VL) region having the amino acid sequence set forth in SEQ ID NO:30;
- (b) a heavy chain variable (VH) region having the amino acid sequence set forth in SEQ ID NO:27, and a light chain variable (VL) region having the amino acid sequence set forth in SEQ ID NO:30;
- or
- (c) a heavy chain variable (VH) region having the amino acid sequence set forth in SEQ ID NO:27, and a light chain variable (VL) region having the amino acid sequence set forth in SEQ ID NO:31;
- wherein the binding agent specifically binds to human CSPG4.
2 more elements
A conjugate comprising:
- (a) a binding agent comprising:
- (i) a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:25, and a light chain variable region having the amino acid sequence set forth in SEQ ID NO:30;
- (ii) a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:27, and a light chain variable region having the amino acid sequence set forth in SEQ ID NO:30;
- or
- (iii) a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:27, and a light chain variable region having the amino acid sequence set forth in SEQ ID NO:31;
- wherein the binding agent specifically binds to human CSPG4;
- (b) at least one linker attached to the binding agent;
- and
- (c) at least one cytotoxic agent attached to each linker.
6 more elements
Dependencies are inferred from the claim text.